铂类化疗药物的耐药机制

        小结 
        铂类耐药是一个多基因、多因素和多步骤的复杂过程 ,随着铂类耐药的深入研究和耐药机制的逐步明确，选择个体化治疗，提高化疗疗效。
参考文献
[1]Chen HY ,Shao CJ, Chen FR, et al. Role of ERCC1 promoter hypermethylation in drugresistance to cisplatin in human gliomas.Int J Cancer.2010,126(8):1944 -1954.
[2]单利,韩志刚,刘莉,等.晚期非小细胞肺癌ERCC1和BRCA1的表达及与顺铂耐药性的临床研究，肿瘤[J],2009,29(6):15.
[3]徐大洲,茅国新,ERCC1在胃癌中的表达及预后意义,交通医学[J],2010,24(4):375-380. [4]Park DJ ,Stoehlmacher J ,Zhang W, et al .A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer [J].Cancer Res,2001,61,(24):8654-8658.
[5]Stevens EV,Nishizuka S,Antony S,et a1.Predicting cisplatin and trabect-edin drug sensitivity in ovarian and colon cancers[J].Mol CancerTher,2008,7(I):10-18.
[6]Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy[J]. J Clin Oncol, 2004,22(13):2594-2601.
[7]Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells[J]. Br Cancer,2003,88:1285-1291.
[8]Strathdee G,Mackean MJ,and M,et al.A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer[J]. Oncogene,1999,18(14): 2335 –
2341. 
[9]董汉章,杨力,夏建国,等.Survivin在胃癌SGC7901顺铂耐药中的作用,南京医科大学学报, 2007,27(9):927-930.
[10]Lopes RB,Cangeswaran R,McNeish IA.et a1.Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy[J].Int J Can-cer,2007,120(11):2344-2352.
[11]Siddik ZH,Cisplatin:mode of cytotoxic action and molecular basis of resistance [J].Oncogene, 2003,22(47):7265-7279.
[12]魏学明,顾国利,任力,等.多药耐药基因产物在胃癌组织中的表达及意义[J].中国普外基础与临床杂志2009:16(12),1000-1004.
[13]吴晴,李兆坤,李大卫,等.缺氧诱导因子-1参与胃癌多要耐药的机制,中华实验外科杂志[J]. 2009,26(10):1338-1340.